Trastuzumab (for HER2+ Adenocarcinoma)
Treatment for Esophageal Cancer
Typical Dosage: Trastuzumab 8 mg/kg loading dose IV, then 6 mg/kg IV every 3 weeks.
Effectiveness
60%
Safety Score
55%
Clinical Trials
15
Participants
3K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
Trastuzumab 8 mg/kg loading dose IV, then 6 mg/kg IV every 3 weeks.
Time to Effect
1-2 months
Treatment Duration
until progression or unacceptable toxicity (months to 1-2 years)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
12(Treat 12 patients to see 1 additional successful outcome)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$70,000
Monitoring:$8,000
Side Effect Mgmt:$3,000
Total Annual:$81,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$180,000/QALY
QALYs Gained
0.45
Outcome-Based Costs
Cost per Responder
$172,340.43
Cost per Remission
$1,012,500
Trastuzumab (for HER2+ Adenocarcinoma) Outcomes
for Esophageal Cancer
Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+47%
Remission Rate
+8%
Common Side Effects
Infusion Reactions
+15%
Cardiotoxicity (LVEF decrease)
+7%
Diarrhea
+15%
Fatigue
+40%
Sources:
Active Clinical Trials
5 active trials recruiting for Trastuzumab (for HER2+ Adenocarcinoma) in Esophageal Cancer
TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
NCT05188313RECRUITINGPHASE3
376 participants
INTERVENTIONAL
Amsterdam, Netherlands
Started: Mar 9, 2022
Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer
NCT05965479RECRUITINGPHASE2
25 participants
INTERVENTIONAL
Guildford, United Kingdom +13 more
Started: Apr 10, 2024
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
NCT04704934ACTIVE NOT RECRUITINGPHASE3
490 participants
INTERVENTIONAL
Colegiales, Argentina +155 more
Started: May 21, 2021
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357RECRUITINGPHASE1, PHASE2
768 participants
INTERVENTIONAL
Phoenix, United States +100 more
Started: Jun 3, 2024
Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma
NCT07000253NOT YET RECRUITINGPHASE2, PHASE3
290 participants
INTERVENTIONAL
Amsterdam, Netherlands +1 more
Started: Jan 1, 2026
Completed Clinical Trials
7 completed trials for Trastuzumab (for HER2+ Adenocarcinoma) in Esophageal Cancer
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)
NCT04014075COMPLETEDPHASE2
79 participants
INTERVENTIONAL
Duarte, United States +36 more
Started: Nov 26, 2019
Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer
NCT01522768COMPLETEDPHASE2
42 participants
INTERVENTIONAL
Los Angeles, United States +8 more
Started: Mar 1, 2012
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
NCT02213289COMPLETEDPHASE2
80 participants
INTERVENTIONAL
Chicago, United States
Started: Jan 20, 2015
Identification of Biomarkers for Prediction of Response or Resistance Against Target Therapy in Gastric Cancer
NCT02305043COMPLETED
549 participants
OBSERVATIONAL
Leipzig, Germany
Started: Mar 1, 2014
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
NCT01196390COMPLETEDPHASE3
203 participants
INTERVENTIONAL
Birmingham, United States +633 more
Started: Feb 14, 2011
A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer
NCT01364493COMPLETEDPHASE2
51 participants
INTERVENTIONAL
Beijing, China
Started: May 1, 2011
Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer
NCT01295086COMPLETEDNA
27 participants
INTERVENTIONAL
Aalborg, Denmark +3 more
Started: Mar 1, 2011